First, I should note that as of July 28, 2007, I am
not personally a Symlin user, so be forewarned that I cannot share any personal information on this treatment, rather, I am just the person who started this forum as a place where people can share information on this treatment and their experience, advice, warnings and other info. related to treatment with Symlin.
The
San Diego Union-Tribune, the hometown paper for the city in which Amylin Pharmaceuticals is based, had perhaps one of the more comprehensive stories on Symlin's approval from the FDA, which can be viewed
here.
For background information, I have collected the following list of resources:
Symlin (company operated website)Pretty self-explanatory, this site is operated by the manufacturer(s) of Symlin, although patients should consider the information contained on this website with caution and understanding that truly objective information may be limited at this particular site. For somewhat more balanced information, please refer to the other links here.
http://www.symlin.com/Amylin PharmaceuticalsAmylin Pharmaceuticals, Inc. is a San Diego-based company founded in 1987 responsible for the development and commercialization of Symlin. Although Amylin Pharmaceuticals was the developer of Symlin, the company has partnered with pharmaceutical company Eli Lilly and Company to actually commercialize Symlin. Lilly brings manufacturing and marketing expertise to the partnership, although both companies share profits from the product itself.
http://www.amylin.com/Impact of Pramlintide on Glucose Fluctuations & Postprandial Glucose, Glucagon & Triglyceride Excursions Among Patients With Type 1 Diabetes MellitusIn this study, the addition of pramlintide to insulin therapy reduced excessive 24-hour glucose fluctuations as well as postprandial glucose, glucagon, and triglyceride excursions in patients with type 1 diabetes intensively treated with insulin pumps. *** Note: This study was funded, in part, by the manufacturer. ***
http://care.diabetesjournals.org/cgi/content/full/26/1/1Amylin Replacement With Pramlintide in Types 1 & 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin TherapyA scientific overview of new type 1 diabetes treatment Symlin from the medical journal
Clinical Diabetes.Many insulin-treated diabetic patients still fail to achieve optimal glycemic control and continue to experience problems with hypoglycemia, weight gain, and postprandial hyperglycemia. Adjunctive therapy with pramlintide, a synthetic analog of the human amylin hormone, facilitates a significant improvement of postprandial and overall glycemic control in patients with either type 1 or type 2 diabetes without an increased risk of hypoglycemia or weight gain. *** Note: Co-Authors Christian Weyer, MD, is medical director, and David G. Maggs, MD, MRCP, is senior medical director at Amylin Pharmaceuticals, Inc. ***
http://clinical.diabetesjournals.org/cgi/reprint/20/3/137Effect of Adjunctive Pramlintide Treatment on Treatment Satisfaction in Patients With Type 1 DiabetesThe following article shows that patients with type 1 diabetes had greater satisfaction with treatment after receiving Symlin compared with placebo, according to the results of a study reported in the February 2007 issue of the medical journal
Diabetes Care. *** Note: This study was funded, in part, by the manufacturer. ***
http://care.diabetesjournals.org/cgi/content/full/30/2/210FDA Center for Drug Evaluation and Research Endocronologic and Metabolic Drugs Advisory CommitteeMeeting Summary Minutes for NDA 21-332, Symlin (pramlintide acetate) Amylin Pharmaceuticals, Inc., July 26, 2001.
http://www.fda.gov/OHRMS/DOCKETS/ac/01/minutes/3761m1.htmFDA Presentation for Symlin (pramlintide acetate)Presentation made to the FDA seeking approval of this new treatment for type 1 diabetes by the manufacturer, Amylin Pharmaceuticals, Inc.
http://www.fda.gov/ohrms/dockets/ac/01/slides/3761s1_01_amylin.pptFDA Approval Letter for Symlin (pramlintide acetate)Letter from the FDA regarding Symlin's approval by the drug-regulating agency.
http://www.fda.gov/cder/foi/appletter/2005/021332ltr.pdf